The goal of the Biomaterials Development Center is to reduce implant related infections by bringing a number of innovative infection-resistant biomaterials (or coatings) to clinical application
Small things: promoting or preventing a big problem?
When? October 1 - 2, 2018
Where? Thesinge, a picturesque rural village, 9 km north of the city of Groningen...
In September 2016 the UMCG Groningen started an EU funded project PRONKJEWAIL. The research aims to protect people who are particularly susceptible to infectious diseases. PRONKJEWAIL (‘a real gem’) w...
Biomaterial implants are successfully applied in modern medicine to restore human function; examples being total hip replacements, vascular grafts or dental implants. In addition, biomaterial devices ...
Over 60% of all human infections treated by physicians are due to biofilms; examples being oral biofilms and biofilms involved in a variety of pathological conditions like for instance osteomyelitis, ...
Biofilms: are you being surfaced?
When? September 12 - 13, 2016
Where? Thesinge, a picturesque rural village, 9 km north of the city of Groningen, The Netherlands
...
Lost a tooth? Soon your dentist could print you another – and it’ll help keep your mouth clean, too.
Getting fitted for a false tooth or other dental treatment tends to involve a mouthful of foul-t...
We at the University Medical Center Groningen (UMCG) and the University of Groningen (RUG), together with its collaborators, are proven world leaders in designing and developing infection resistant biomaterials.
Scientifically, we have excelled over the years and achieved many of our research goals. Now comes the challenge of fulfilling our societal responsibility to patients under the umbrella of a Biomaterials Development Center, integrating the unique scientific research and clinical practices Groningen has to offer.
The Biomaterials Development Center is a platform where academia and industry can partner. Guiding innovation at early stages of development and making strategic go/ no go decisions during development phases of biomaterials, we aim to ensure that innovation is not lost in translation, but efficiently transferred to solve clinical problems.
In Groningen we are proud of the transfer of knowledge between our academics and clinicians. However, now is the time to add the final piece of the puzzle and involve industry in achieving our goals and partner with us under the Biomaterials Development Center.
Prof. Henk Busscher
Head of Department
Biomedical engineering UMCG
Introduction
Loss of body function is inevitably associated with ageing and often beyond natural repair. This is considered unacceptable in the 21th century.
As imaging instrumentation at the
UMCG is ever more available and
increasingly more state of the art,
both in preclinical (animal facility)
and clinical settings, translation of
tracer development to the clinic
is becoming a very strong asset of
the UMCG.
Reducing the validation costs for
infection-resistant biomaterials in
clinical trials is a major challenge
for society, and something the
BDC aims to resolve
The University of Groningen is an
internationally oriented university
with 30,000 students. It is over
400 years old and is well known to
be innovative and research-driven.
It is rooted as the number-one
knowledge hub for the Northern
Netherlands.
The UMCG is a city within a city:
it is one of the largest hospitals in the
World; located on the Healthy Ageing
Campus Netherlands. The Campus
extends over an area of around 30
hectares and is the beating heart of the
regional theme of Healthy Ageing.
More than a decade of investment in
high-speed internet, cable and digital
communication systems, as well as
the rapid adoption of state-of-the-art
computer and cell phone technologies,
have created an ideal base for
companies seeking to take advantage
of modern technology.